An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
This article has no abstract
Epistemonikos ID: af5ba02214f47ada2ab5d5f744fc02873b35316c
First added on: Oct 15, 2026